AstraZeneca PLC (AZN)vsPrenetics Global Ltd (PRE)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
PRE
Prenetics Global Ltd
$16.71
-4.02%
HEALTHCARE · Cap: $310.15M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 63477% more annual revenue ($58.74B vs $92.39M). AZN leads profitability with a 17.4% profit margin vs -63.1%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PRE
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+17.4%
Fair Value
$25.92
Current Price
$16.71
$9.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 248.6% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -31.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : PRE
The strongest argument for PRE centers on Revenue Growth, Price/Book. Revenue growth of 248.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : PRE
The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while PRE is a hypergrowth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
PRE is growing revenue faster at 248.6% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 35/100), backed by strong 17.4% margins. PRE offers better value entry with a 17.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Prenetics Global Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Prenetics Global Ltd (PRE) is a premier health technology innovator focused on delivering advanced genetic and diagnostic testing solutions that empower consumers and healthcare professionals with critical health insights. With a diverse portfolio of state-of-the-art testing services and integrated digital health offerings, the company has seen significant international growth, fueled by strategic partnerships and a strong commitment to ongoing research and development. As a frontrunner in the personalized medicine space, Prenetics is ideally positioned to capitalize on the increasing demand for accessible and actionable health information, representing a compelling investment opportunity in the dynamic healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?